Mylan N.V. announced that the FDA has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL...
The US Court of Appeals has finally invalidated patent protection for Teva’s multiple sclerosis drug Copaxone (glatiramer acetate injection) for...
Glatiramer acetate (GA; Copaxone) is a random copolymer of glutamic acid, lysine, alanine, and tyrosine used for the treatment of patients with multiple sclerosis (MS).
Glatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) (see Section 5.1 for important information on the population for which efficacy has been established). Glatiramer acetate is not indicated in primary or secondary progressive MS.
Glatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) (see section 5.1 for important information on the population for which efficacy has been established). Glatiramer acetate is not indicated in primary or secondary progressive MS.
Teva Pharmaceutical Industries Ltd.,has announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week...
Glatiramer acetate (GA) is a first-line therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). It has a well-characterized long-term safety profile and established efficacy, with over 2 million patient-years of exposure.
Background: In recent years the impact of disease-modifying drugs on long-term progression in multiple sclerosis (MS) was assessed both in observational studies and in extension of randomized controlled trial (RCT).
Copaxone is indicated for the treatment of relapsing forms of multiple sclerosis (MS) (see section 5.1 for important information on the population for which efficacy has been established). Copaxone is not indicated in primary or secondary progressive MS.
Novartis announced at ECTRIMS conference findings from an international multiple sclerosis (MS) registry and a US health claims data base...